Skinvisible, Inc. Share Price

Equities

SKVI

US8307032032

Personal Products

Market Closed - OTC Markets 15:22:16 01/05/2024 BST 5-day change 1st Jan Change
0.062 USD -38.00% Intraday chart for Skinvisible, Inc. +1.64% -26.01%
Sales 2022 279K 22.26M Sales 2023 20K 1.59M Capitalization 380K 30.31M
Net income 2022 -1M -79.71M Net income 2023 -2M -159M EV / Sales 2022 14.7 x
Net Debt 2022 3.63M 290M Net Debt 2023 6.15M 490M EV / Sales 2023 327 x
P/E ratio 2022
-0.37 x
P/E ratio 2023
-0.16 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 96.6%
More Fundamentals * Assessed data
Dynamic Chart
Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Skinvisible, Inc. Auditor Raises 'Going Concern' Doubt CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 day-38.00%
1 week+1.64%
Current month-38.00%
1 month-31.11%
3 months-22.50%
6 months+1.64%
Current year-26.01%
More quotes
1 week
0.06
Extreme 0.062
0.10
1 month
0.06
Extreme 0.061
0.10
Current year
0.06
Extreme 0.055
0.10
1 year
0.06
Extreme 0.055
0.14
3 years
0.06
Extreme 0.055
0.37
5 years
0.01
Extreme 0.012
0.37
10 years
0.01
Extreme 0.012
16.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 75 04/03/98
Public Communications Contact 61 -
Members of the board TitleAgeSince
Chief Executive Officer 75 04/03/98
Director/Board Member 51 21/09/17
More insiders
Date Price Change Volume
01/05/24 0.062 -38.00% 1,595

Delayed Quote OTC Markets, May 01, 2024 at 03:22 pm

More quotes
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.
More about the company